Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Cannabis and lung cancer

A. S. Reece
European Respiratory Journal 2008 32: 238-239; DOI: 10.1183/09031936.00024408
A. S. Reece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

The elegant and eminent study by Aldington et al. 1 of the Cannabis and Respiratory Disease Research group is to be welcomed at a time when, as the authors rightly point out, there are many suggestive case studies and clinical series on lung cancer, and indeed other tumours, occurring particularly at younger ages in past and present smokers of cannabis. The authors' careful methodology and succinct summary of much of the relevant literature in relation to this subject is a relevant and timely addition to the literature, particularly in the context of increased interest in this subject in both lay and professional circles.

The point made by Aldington et al. 1 in relation to the lack of research into the molecular underpinnings of cannabis-related oncogenesis is particularly relevant at a period in research history when the molecular bases of disease have received unprecedented attention. It is to be expected that their elucidation might lead to better understanding of the mechanisms of common disorders including cancer and, in time, improved therapeutics. Interestingly, cannabis use also featured in our case review of malignant and pre-malignant disorders of the cervix uteri in an addicted population 2.

From the vast published literature on cannabis, several main pathways emerge as being most relevant to oncogenesis in addition to the obvious factors related to carcinogen content and smoking technique. Cancer is defined as a disorder of uncontrolled cell growth, and mechanisms of DNA toxicity and dysregulated DNA replication are its genetic hallmarks. Damage to DNA, therefore, as might occur with free oxygen- and nitrogen-centred radicals, is relevant to molecular pathogenesis. Indeed, normal signalling of the endogenous cannabinoid ligand, anandamide, via the oxidative damage of guanine to 6-oxoguanine and its routine restoration by base excision repair has been described in cultured cells 3. Free radical generation both at receptor binding (S.T. Carney, North Carolina Central University, Durham, NC, USA; personal communication) and by mitochondrial uncoupling 4 has been demonstrated.

Cannabis is widely acknowledged to stimulate the mitogen activated protein kinase (MAPK) pathway, which is a major stimulant of developmental and malignant cell growth. MAPK dysregulation has been identified clinically in tuberous sclerosis, neurofibromatosis and acute myelomonocytic leukaemia (AMML), and greatly increased incidences of AMML have been identified in paediatric populations after in utero maternal exposure to cannabis 5. There are reports in sub-acutely “stoned” animals (a use pattern reminiscent of that seen in many patients) that heavy cannabis use is associated with severe telomeric (end-chromosomal) damage in male germ cells 6. The burgeoning literature on telomeres demonstrates that this field is intimately involved in pathways of both ageing and tumourigenesis. Key DNA repair enzymes topoisomerase II 7 and Rad51 have been shown to be inhibited by cannabinoids. Germ line chromosomal abnormalities in addition to MAPK stimulation constitute putative pathways of inheritable oncogenesis.

Reports that cannabis is associated with severe dental disease 8, osteoporosis 9 and mental illness 10, together with unpublished studies from our clinic showing accelerated vascular ageing in heavy cannabis smokers, suggest that cannabis may be modifying the ageing process itself. Ageing is of course the leading risk factor for most nonpaediatric tumours. It is well known that there is extensive cross-talk including heterodimerisation at the cell membrane between the cannabinoid type 1 receptor and other guanosine triphosphate-coupled receptors including adrenergic receptors which are well known to be involved in ageing processes. Cannabinoids are also known to induce cell cycle arrest, senescence and apoptotic cell programmes. Senescence is increasingly associated with oncogenic induction 11. Cannabis has well-recognised immunosuppressive properties 12 that are likely to be of relevance to tumour surveillance activities of the immune system, both in the pre-clinical stages and in the metastatic spread of advanced disease.

Sleep disturbances are clinically prominent and highly problematic in cannabis-dependent patients and imply significant disruption to the cellular circadian genetic clock mechanisms 13. Circadian disruption has been linked to acceleration of the ageing process in mammals 14. Finally, it is not widely appreciated that histone deacetylases, central regulators of the epigenetic code, have been shown to be major regulators of ageing 15 (including neurogenesis 16), psychopathology 17, addiction 16 and cancer 18.

In summary, while cannabinoids, and especially smoked inhaled cannabis, are strongly implicated in oncogenesis by several molecular pathways, there are multiple leads that might prove useful for mechanistic exploration and perhaps, one day, therapeutic exploitation of the cannabinoid system.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Aldington S, Harwood M, Cox B, et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008;31:280–286.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Reece A. Lifetime prevalence of cervical neoplasia in addicted and medical patients. Aust NZ J Obstet Gynaecol 2007;47:419–423.
      OpenUrlPubMedWeb of Science
    3. ↵
      Sarker KP, Obara S, Nakata M, Kitajima I, Maruyama I. Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett 2000;472:39–44.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Sarafian TA, Habib N, Oldham M, et al. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 2006;290:L1202–L1209.
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer 1989;63:1904–1911.
      OpenUrlPubMedWeb of Science
    6. ↵
      Zimmerman AM, Zimmerman S, Raj AY. Effects of cannabinoids on spermatogenesis in mice. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S, eds. Marihuana and Medicine. Totawa, Humana Press, 1999; pp. 347–358
    7. ↵
      Kogan NM, Schlesinger M, Priel E, et al. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther 2007;6:173–183.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Hujoel PP. Destructive periodontal disease and tobacco and cannabis smoking. JAMA 2008;299:574–575.
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      Idris AI, van 't Hof RJ, Greig IR, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005;11:774–779.
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319–328.
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513–522.
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006;1:280–295.
      OpenUrlCrossRefPubMed
    13. ↵
      O'Leary DS, Block RI, Turner BM, et al. Marijuana alters the human cerebellar clock. Neuroreport 2003;14:1145–1151.
      OpenUrlCrossRefPubMedWeb of Science
    14. ↵
      Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes Dev 2006;20:1868–1873.
      OpenUrlAbstract/FREE Full Text
    15. ↵
      Guarente L, Picard F. Calorie restriction – the SIR2 connection. Cell 2005;120:473–482.
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      Renthal W, Maze I, Krishnan V, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007;56:517–529.
      OpenUrlCrossRefPubMedWeb of Science
    17. ↵
      Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007;8:355–367.
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457–463.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 32 Issue 1 Table of Contents
    European Respiratory Journal: 32 (1)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Cannabis and lung cancer
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Cannabis and lung cancer
    A. S. Reece
    European Respiratory Journal Jul 2008, 32 (1) 238-239; DOI: 10.1183/09031936.00024408

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Cannabis and lung cancer
    A. S. Reece
    European Respiratory Journal Jul 2008, 32 (1) 238-239; DOI: 10.1183/09031936.00024408
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    • Optimised surveillance of bronchial dysplasia in risky population
    • Reply: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society